{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:13:41Z","timestamp":1789586021921,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.xphs.2018.08.024","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T13:55:13Z","timestamp":1536242113000},"page":"3179-3186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice"],"prefix":"10.1016","volume":"107","author":[{"given":"Sanjida","family":"Mahjabeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolya Kukut","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris M.","family":"Benbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila","family":"Garcia-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1128\/CDLI.8.2.209-220.2001","article-title":"Cell-mediated immune response to human papillomavirus infection","volume":"8","author":"Scott","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2018.08.024_bib3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J\u00a0Clin Virol"},{"issue":"1","key":"10.1016\/j.xphs.2018.08.024_bib4","doi-asserted-by":"crossref","first-page":"e0165276","DOI":"10.1371\/journal.pone.0165276","article-title":"Pregnancy outcomes after treatment for cervical cancer precursor lesions: an observational study","volume":"12","author":"Weinmann","year":"2017","journal-title":"PLoS One"},{"issue":"5 Pt 1","key":"10.1016\/j.xphs.2018.08.024_bib5","first-page":"1058","article-title":"Pregnancy outcome after loop electrosurgical excision procedure: a systematic review","volume":"102","author":"Crane","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.xphs.2018.08.024_bib6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1097\/AOG.0000000000000287","article-title":"Treatment of cervical precancers: back to basics","volume":"123","author":"Khan","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.xphs.2018.08.024_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2015.104","article-title":"Cervical cancer: squamocolumnar junction ablation\u2013tying up loose ends?","volume":"12","author":"Herfs","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.xphs.2018.08.024_bib8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10637-005-2901-5","article-title":"Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists","volume":"23","author":"Benbrook","year":"2005","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.xphs.2018.08.024_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/gyno.2001.6196","article-title":"Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus","volume":"81","author":"Bae","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.xphs.2018.08.024_bib10","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1158\/0008-5472.CAN-09-0913","article-title":"Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells","volume":"69","author":"Masamha","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.xphs.2018.08.024_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1940-6207.CAPR-13-0171","article-title":"Chemoprevention of colon and small intestinal tumorigenesis in APC(min\/+) mice by SHetA2 (NSC721689) without toxicity","volume":"6","author":"Benbrook","year":"2013","journal-title":"Cancer Prev Res"},{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.xphs.2017.09.018","article-title":"Optimization of a vaginal suppository formulation to deliver SHetA2 as a novel treatment for cervical dysplasia","volume":"107","author":"Mahjabeen","year":"2018","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.08.024_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mrgentox.2012.03.009","article-title":"Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen","volume":"746","author":"Doppalapudi","year":"2012","journal-title":"Mutat Res"},{"issue":"3","key":"10.1016\/j.xphs.2018.08.024_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/01480545.2012.710632","article-title":"Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs","volume":"36","author":"Kabirov","year":"2013","journal-title":"Drug Chem Toxicol"},{"issue":"7","key":"10.1016\/j.xphs.2018.08.024_bib15","first-page":"1294","article-title":"Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice","volume":"57","author":"Smith-McCune","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib17","first-page":"13","article-title":"Standardization of the Whitten Effect to induce susceptibility to Neisseria gonorrhoeae in female mice","volume":"40","author":"Dalal","year":"2001","journal-title":"Contemp Top Lab Anim Sci"},{"key":"10.1016\/j.xphs.2018.08.024_bib18","first-page":"e4389","article-title":"Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification","volume":"67","author":"McLean","year":"2012","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.xphs.2018.08.024_bib19","article-title":"Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples","author":"Hatipoglu","year":"2018","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.xphs.2018.08.024_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.hoc.2011.11.005","article-title":"Management of cervical precancers: a global perspective","volume":"26","author":"Echelman","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib21","first-page":"210","article-title":"Morphometric study of intraepithelial neoplasia of the uterine cervix","volume":"60","author":"Abdul-Karim","year":"1982","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.xphs.2018.08.024_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s13346-017-0395-2","article-title":"Vaginal drug delivery for the localised treatment of cervical cancer","volume":"7","author":"Major","year":"2017","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"10.1016\/j.xphs.2018.08.024_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10637-008-9175-7","article-title":"Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in\u00a0vitro and in\u00a0vivo","volume":"27","author":"Myers","year":"2009","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.xphs.2018.08.024_bib24","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1158\/1535-7163.MCT-06-0279","article-title":"Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria","volume":"6","author":"Liu","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.xphs.2018.08.024_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-017-0550-0","article-title":"Development of a dietary formulation of the SHetA2 chemoprevention drug for mice","volume":"36","author":"Benbrook","year":"2017","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.xphs.2018.08.024_bib26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-08-1069","article-title":"Development of flexible-heteroarotinoids for kidney cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.xphs.2018.08.024_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/00498254.2016.1214885","article-title":"Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis","volume":"47","author":"Wang","year":"2017","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.xphs.2018.08.024_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmpb.2010.03.007","article-title":"Modelling the double peak phenomenon in pharmacokinetics","volume":"104","author":"Godfrey","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"issue":"8","key":"10.1016\/j.xphs.2018.08.024_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0090-9556(24)15233-6","article-title":"A\u00a0double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration","volume":"27","author":"Wang","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.xphs.2018.08.024_bib30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/j.1552-4604.1993.tb03921.x","article-title":"Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles","volume":"33","author":"Charman","year":"1993","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2018.08.024_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1248\/bpb1978.10.384","article-title":"Prediction of plasma concentration profile during single and repeated skin applications of indomethacin and its calcium salt ointments","volume":"10","author":"Ogiso","year":"1987","journal-title":"J\u00a0Pharmacobiodyn"},{"issue":"5","key":"10.1016\/j.xphs.2018.08.024_bib32","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s11095-016-1871-y","article-title":"Characterization of supersaturated danazol solutions\u2013impact of polymers on solution properties and phase transitions","volume":"33","author":"Jackson","year":"2016","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2018.08.024_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acs.molpharmaceut.5b00652","article-title":"Dissolution of danazol amorphous solid dispersions: supersaturation and phase behavior as a function of drug loading and polymer type","volume":"13","author":"Jackson","year":"2016","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2018.08.024_bib34","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1021\/acs.cgd.7b00237","article-title":"Maintaining supersaturation of active pharmaceutical ingredient solutions with biologically relevant bile salts","volume":"17","author":"Lu","year":"2017","journal-title":"Cryst Growth Des"},{"key":"10.1016\/j.xphs.2018.08.024_bib35","series-title":"Reproducci\u00f3n en animales de laboratorio","author":"Galassi-Ger\u00e9z","year":"2004"},{"key":"10.1016\/j.xphs.2018.08.024_bib36","series-title":"Fundamentos te\u00f3rico pr\u00e1cticos de la citolog\u00eda exfoliativa en medicina veterinaria","author":"Hern\u00e1ndez-Pichardo","year":"1999"},{"key":"10.1016\/j.xphs.2018.08.024_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejpb.2018.07.004","article-title":"Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration","volume":"130","author":"Mahjabeen","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2018.08.024_bib38","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/nrdp.2015.4","article-title":"Menopause","volume":"1","author":"Davis","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.xphs.2018.08.024_bib39","series-title":"Endotext [Internet], The Normal Menstrual Cycle and the Control of Ovulation","author":"Reed","year":"2000"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:24:54Z","timestamp":1758360294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918305252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0022354918305252"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.08.024","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}